[1] WHO (2014) Antimicrobical Resistance: Global Report on Surveillance. World Health Organization, Geneva, 1-257.
[2] (2013) Antibiotic Resistance Threats in the USA. U.S. Department of Health and Human Services Centers for Disease Control and Prevention, Atlanta, 1-114.
[3] Ducel, G., Fabry, J. and Nicolle, L. (2002) Prevention of Hospital-Acquired Infections: A Practical Guide. World Health Organization, Geneva, 1-64.
[4] Coella, R., Glenister, H., Fereres, J., Bartlett, C., Leigh, D., Sedgwick, J. and Cooke, E.M. (1993) The Cost of Infection in Surgical Patients: A Case-Control Study. Journal of Hospital Infection, 25, 239-250.
http://dx.doi.org/10.1016/0195-6701(93)90110-L
[5] Rosenthal, V.D., Maki, D.G., Mehta, Y., Apisarnthanarak, A., Fisher, D., Medeiros, E.A., et al. (2012) International Nosocomial Infection Control Consortium (INICC) Report, Data Summary of 36 Countries, for 2004-2009. American Journal of Infection Control, 40, 396-407.
http://dx.doi.org/10.1016/j.ajic.2011.05.020
[6] Lu, T.K. and Koeris, M.S. (2011) The Next Generation of Bacteriophage Therapy. Current Opinion in Microbiology, 14, 524-531.
http://dx.doi.org/10.1016/j.mib.2011.07.028
[7] Keen, E.C. (2012) Phage Therapy: Concept to Cure. Frontiers in Microbiology, 3, 1-3.
http://dx.doi.org/10.3389/fmicb.2012.00238
[8] Dublanchet, A. and Bourne, S. (2007) The Epic of Phage Therapy. Canadian Journal of Infectious Disease and Medical Microbiology, 18, 15-18.
[9] Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S. and Abendon, S.T. (2010) Phage Therapy in Clinical Practice: Treatment of Human Infections. Current Pharmaceutical Biotechnology, 11, 69-86.
http://dx.doi.org/10.2174/138920110790725401
[10] Abedon, S.T., Kuhl, S.J., Blasdel, B.G. and Kutter, E.M. (2011) Phage Treatment of Human Infections. Bacteriophage, 1, 66-85.
http://dx.doi.org/10.4161/bact.1.2.15845
[11] Chanishvili, N. (2012) A Literature Review of the Practical Application of Bacteriophage Research. Nova Science Publishers, Hauppauge.
[12] Wittebole, X., Roock, S.D. and Opal, S.M. (2014) A Historical Overview of Bacteriophage Therapy as an Alternative to Antibiotics for the Treatment of Bacterial Pathogens. Virulence, 5, 226-235.
http://dx.doi.org/10.4161/viru.25991
[13] Chan, K.B., Abedon, S.T. and Loc-Carrillo, C. (2013) Phage Cocktails and the Future of Phage Therapy. Future Microbiology, 8, 769-783.
http://dx.doi.org/10.2217/fmb.13.47
[14] Merril, C.R., Scholl, D. and Adhya, S.L. (2003) The Prospect for Bactreriopharge Therapy in Western Medicine. Nature Reviews in Drug Discovery, 2, 489-497.
http://dx.doi.org/10.1038/nrd1111
[15] Fruciano, D.E. and Bourne, S. (2007) Phage as an Antimicrobial Agent: D’Herelle’s Heretical Theories and Their Role in the Decline of Phage Prophylaxis in the West. Canadian Journal of Infectious Disease and Medical Microbiology, 18, 19-26.
[16] Harper, D.R., Anderson, J. and Enright, M.C. (2011) Phage Therapy: Delivering on the Promise. Therapeutic Delivery, 2, 935-947.
http://dx.doi.org/10.4155/tde.11.64
[17] Borysowski, J. (2014) Phage Therapy: Current Research and Applications. Caister Academic Press, Norfolk.
[18] Atterbury, R.J. (2009) Bacteriophage Biocontrol in Animals and Meat Products. Microbial Biotechnology, 2, 601-612. http://dx.doi.org/10.1111/j.1751-7915.2009.00089.x
[19] Traore, H. (2007) Low-Cost Rapid Detection of Rifampicin Resistant Tuberculosis Using Bacteriophage in Kampula, Uganda. Annals of Clinical Microbiology and Antimicrobials, 6, 1-6.
http://dx.doi.org/10.1186/1476-0711-6-1
[20] Pai, M. and Kalantri, S.P. (2005) Bacteriophage-Based Tests for Tuberculosis. Indian Journal of Medical Microbiology, 23, 149-150.
http://dx.doi.org/10.4103/0255-0857.16584
[21] Albert, H., Trollip, A.P., Mole, R.J., Hatch, S.J. and Blumberg, L. (2002) Rapid Indication of Multidrug-Resistant Tuberculosis from Liquid Cultures Using FAST Plaque TB-RIF, a Manual Phage-Based Test. International Journal of Tuberculosis and Lung Disease, 6, 523-528.
[22] Albert, H., Trollip, A., Seaman, T. and Mole, R.J. (2004) Simple, Phage-Based (FAST Plaque) Technology to Determine Rifampicin Resistance of Mycobacterium tuberculosis Directly from Sputum. International Journal of Tuberculosis and Lung Disease, 8, 1114-1119.
[23] Jain, P., Thaler, D.S., Maiga, M., Timmins, G.S., Bishai, W.R., Hatfull, G.F., Larsen, M.H. and Jacobs, W.R. (2011) Reporter Phage and Breath Tests: Emerging Phenotypic Assays for Diagnosing Active Tuberculosis, Antibiotic Resistance, and Treatment Efficacy. Journal of Infectious Disease, 204, 142-150.
http://dx.doi.org/10.1093/infdis/jir454
[24] Schmelcher, M. and Loessner, M.J. (2014) Application of Bacteriophages for Detection of Foodborne Pathogens. Bacteriophage, 4, e28137.
[25] Hendrix, R.W. (1999) Evolutionary Relationships among Diverse Bacteriophages and Prophages—All the World’s a Phage. Proceedings of the National Academy of Sciences of the United States of America, 96, 2192-2197.
http://dx.doi.org/10.1073/pnas.96.5.2192
[26] Frenkel, D. and Solomon, B. (2001) Filamentous Phage as Vector-Mediated Antibody Delivery to the Brain. Proceedings of the National Academy of Sciences of the United States of America, 99, 5675-5679.
http://dx.doi.org/10.1073/pnas.072027199
[27] Dubos, R.J., Straus, J.H. and Pierce, C. (1943) The Multiplication of Bacteriophage in Vivo and Its Protective Effect against an Experimental Infection with Shigella dysenteriae. Journal of Experimental Medicine, 78, 161-168.
http://dx.doi.org/10.1084/jem.78.3.161
[28] Merril, C.R., Friedman, T.B., Attallah, A.F., Geier, M.R., Krell, K. and Yarkin, R. (1972) Isolation of Bacteriophages from Commercial Sera. In Vitro, 8, 91-93.
http://dx.doi.org/10.1007/BF02615965
[29] Merril, C.R. (1975) Phage in Human Vaccines. Science Magazine, 188, 8.
http://dx.doi.org/10.1126/science.188.4183.8
[30] Kolata, G.B. (1975) Phage in Live Virus Vaccines: Are They Harmful to People? Science Magazine, 187, 522-523.
http://dx.doi.org/10.1126/science.187.4176.522
[31] Milstien, B.J., Walker, J.R. and Petricciane, J.C. (1977) Bacteriophages in Live Virus Vaccines: Lack of Evidence for Effects on the Genome of Rhesus Monkeys. Science Magazine, 197, 469-470.
http://dx.doi.org/10.1126/science.406673
[32] Hung, C.H., Kuo, C.F., Wang, C.H., Wu, C.M. and Tsao, N. (2011) Experimental Phage Therapy in Treating Klebsiella pneumoniae-Mediated Liver Abscesses and Bacteremia in Mice. Antimicrobial Agents and Chemotherapy, 55, 1358-1365.
http://dx.doi.org/10.1128/AAC.01123-10
[33] Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., Carlton, R. and Merril, C.R. (2002) Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus faecium. Infection and Immunology, 70, 204-210.
http://dx.doi.org/10.1128/IAI.70.1.204-210.2002
[34] Gupta, R. and Prasad, Y. (2011) Efficacy of Polyvalent Bacteriophage P-27/HP to Control Multidrug Resistant Staphylococcus aureus Associated with Human Infections. Current Microbiology, 62, 255-260.
http://dx.doi.org/10.1007/s00284-010-9699-x
[35] Wang, J., Hu, B., Xu, M., Yan, Q., Lui, S., Zhu, X., Sun, Z., Tao, D., Ding, L., Reed, E., Gong, J., Li, Q. and Hu, J. (2005) Therapeutic Effectiveness of Bacteriophages in the Rescue of Mice with Extended Spectrum β-Lactamase-Producing Escherichia coli Bacteremia. International Journal of Molecular Medicine, 17, 347-355.
[36] Wagenaar, J.A., Van Bergen, M.A.P., Mueller, M.A., Wassenaar, T.M. and Carlton, R.M. (2005) Phage Therapy Reduces Campylobacter jejuni Colonization in Broilers. Veterinary Microbiology, 109, 275-283.
http://dx.doi.org/10.1016/j.vetmic.2005.06.002
[37] Sunagar, R., Patil, S.A. and Chandrakanth, R.K. (2010) Bacteriophage Therapy for Staphylococcus aureus Bacteremia in Streptozotocin-Induced Diabetic Mice. Research in Microbiology, 161, 854-860.
http://dx.doi.org/10.1016/j.resmic.2010.09.011
[38] Barrow, P., Lovell, M. and Berchieri Jr., A. (1998) Use of Lytic Bacteriophage for Control of Experimental Escherichia coli Septicemia and Meningitis in Chickens and Calves. Clinical and Diagnostic Laboratory Immunology, 5, 294-298.
[39] Merril, C., Biswas, B., Carlton, R.C., Jensen, N., Greed, G.J., Zullo, S. and Adhya, S. (1996) Long-Circulating Bacteriophage as Antibacterial Agents. Proceedings of the National Academy of Sciences, 93, 3188-3192.
http://dx.doi.org/10.1073/pnas.93.8.3188
[40] Inchley, C.J. (1969) Activity of Mouse Kupffer Cells Following Intravenous Injection of T4 Bacteriophage. Clinical and Experimental Immunology, 5, 173-187.
[41] Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Parys, L.V., Lavigne, R., Volckaert, G., Mattheus, W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D. and Vaneechoutte, M. (2009) Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 4, e4944.
[42] Knouf, E.G., Ward, W.E., Reichle, P.A., Bower, A.G. and Hamilton, P.M. (1946) Treatment of Typhoid Fever with Type Specific Bacteriophage. Journal of the American Medical Association, 132, 134-138.
http://dx.doi.org/10.1001/jama.1946.02870380016006
[43] Verbeken, G., Pirnay, J.P., Lavigne, R., Jennes, S., De Vos, D., Casteels, M. and Huys, I. (2014) Call for a Dedicated European Legal Framework for Bacteriophage Therapy. Archivum Immunologiae et Therapiae Experimentalis, 62, 117-129.
http://dx.doi.org/10.1007/s00005-014-0269-y
[44] Pimay, J.P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., Van den Mooter, G., Buckling, A., Dabarbieux, L., Pouillot, F., Azeredo, J., Kutter, E., Dublanchet, A., Gorski, A. and Adamia, R. (2011) The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure? Pharmaceutical Research, 28, 934-937.
http://dx.doi.org/10.1007/s11095-010-0313-5
[45] Parracho, H., Burrowes, B., Enright, M., McConville, V. and Harper, D. (2012) The Role of Regulated Clinical Trials in the Development of Bacteriophage Therapeutics. Journal of Molecular and Genetic Medicine, 6, 279-286.
http://dx.doi.org/10.4172/1747-0862.1000050
[46] Verbeken, G., Pirnay, J.P., De Vos, D., Jennes, S., Lavigne, R., Casteels, M. and Huys, I. (2012) Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine. Archivum Immunologiae et Therapiae Experimentalis, 60, 161-172.
http://dx.doi.org/10.1007/s00005-012-0175-0
[47] Huys, I., Pirnay, J.P., Lavigne, R., Jennes, S., De Vos, D., Casteels, M. and Verbeken, G. (2013) Paving a Regulatory Pathway for Phage Therapy. EMBO Reports, 14, 947-1022.
http://dx.doi.org/10.1038/embor.2013.163